Vanguard Investments Australia
KRYS icon

Vanguard Investments Australia’s Krystal Biotech KRYS Stock Holding History

Vanguard Investments Australia’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09M Buy
5,615
+285
+5% +$85.2K 0.01% 899
2026
Q1 		$1.38M Buy
+5,330
New +$1.42M ﹤0.01% 1028

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Investments Australia's KRYS Position: Q2 2026 in Review

Vanguard Investments Australia increased its Krystal Biotech (KRYS) stake by 5.3% in Q2 2026, buying an estimated $85.2K and bringing the position to 5,615 shares worth $2.09M. The position accounts for 0.01% of the portfolio, ranked #899.

Vanguard Investments Australia first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vanguard Investments Australia held 5,615 shares of Krystal Biotech worth $2.09M as of Q2 2026.
  • Vanguard Investments Australia bought 285 Krystal Biotech shares in Q2 2026, an estimated $85.2K.
  • Krystal Biotech made up 0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #899 holding.
  • Vanguard Investments Australia first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.